Plant-based production of biopharmaceuticals.
Plants are now gaining widespread acceptance as a general platform for the large-scale production of recombinant proteins. The first plant-derived recombinant pharmaceutical proteins are reaching the final stages of clinical evaluation, and many more are in the development pipeline. Over the past two years, there have been some notable technological advances in this flourishing area of applied biotechnology, as shown by the continuing commercial development of novel plant-based expression platforms. There has also been significant success in tackling some of the limitations of plant bioreactors, such as low yields and inconsistent product quality, that have limited the approval of plant-derived pharmaceuticals.
Fischer
Rainer
R
Institute for Molecular Biotechnology, Biology VII, RWTH Aachen, Worringerweg 1, 52074 Aachen, Germany.
Stoger
Eva
E
Schillberg
Stefan
S
Christou
Paul
P
Twyman
Richard M
RM
D001685:Biological Factors / Q000096:biosynthesis*; D001702:Biopharmaceutics / Q000379:methods*; D019149:Bioreactors; D001709:Biotechnology / Q000379:methods*; D010940:Plant Proteins / Q000096:biosynthesis*; D030821:Plants, Genetically Modified / Q000737:chemistry / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis
D001685:Biological Factors; D010940:Plant Proteins; D011994:Recombinant Proteins